$DYAI "While the market is driven by the rising prevalence of cancer and genetic disorders, the availability of funding for gene therapy development, the effectiveness of viral vectors in gene therapy delivery and ongoing research into viral vector–based gene and cell therapies, the high costs of gene therapies (currently ranging between USD 500,000 and USD 1.5 million) and short shelf-life of viral vectors is currently a matter of significant concern to viral vector manufacturers." pharmasalmanac.com/articles...
  • 6
  • 6